摘要
目的:为阐明免疫检查点抑制剂在GBM管理中的作用 方法:通过在PubMed数据库以及已在临床试验中注册的试验中检索英文文献来获得GBM中免疫检查点抑制剂的临床前和临床试验信息,gov和摘要最近发表在国际大会中。 结果:免疫检查点抑制剂可能在设计未来GBM管理中免疫治疗方法起到了关键的作用。 结论:免疫检查点抑制剂可能是GBM中一个具有潜力的治疗方案。
关键词: 免疫治疗,多形性成胶质瘤细胞,检查点,放疗,PD-1,CTLA-4,ipilimumab
图形摘要
Current Cancer Drug Targets
Title:New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Volume: 17 Issue: 3
关键词: 免疫治疗,多形性成胶质瘤细胞,检查点,放疗,PD-1,CTLA-4,ipilimumab
摘要: Background: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
Objective: To clarify the role of immune check point inhibitors in GBM management. Methods: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses. Results: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management. Conclusion: Immune check-point inhibitors should be considered a promising treatment option in GBM.Export Options
About this article
Cite this article as:
New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666160813183738
DOI https://dx.doi.org/10.2174/1568009616666160813183738 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
[177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Drug Target Discovery Through Analysis of Laccase Regulatory Networks of Cryptococccus neoformans
Current Enzyme Inhibition Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry Synthesis of New Thiazolyl-Pyrazoline Derivatives and Evaluation of Their Antimicrobial, Cytotoxic and Genotoxic Effects
Letters in Drug Design & Discovery Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Advances in Gene Therapy for Bladder Cancer
Current Gene Therapy Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target
Current Pharmaceutical Biotechnology Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Topoisomerases and Tubulin Inhibitors: A Promising Combination for Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Blockade of Furin Activity and Furin-Induced Tumor Cells Malignant Phenotypes By The Chemically Synthesized Human Furin Prodomain
Current Medicinal Chemistry Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Specific Cytostatic and Cytotoxic Effect of Dihydrochelerythrine in Glioblastoma Cells: Role of NF-κB/β-catenin and STAT3/IL-6 Pathways
Anti-Cancer Agents in Medicinal Chemistry Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry